Data / Drug companies / Nexus Pharmaceuticals LLC
Nexus Pharmaceuticals LLC: 27 products in the FDA NDC directory, labeler code 14789
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Nexus Pharmaceuticals LLC (labeler code 14789) lists 27 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 27 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 30, 2026.
The request: Watch Nexus Pharmaceuticals LLC (FDA labeler code 14789): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 14789
- Products in commercial distribution
- 27
- Packages
- 30
- Finished drugs by generic name
- 15
- Prescription products
- 27
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 2
- Flagged as original packager
- 27 of 27 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- October 14, 2007
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 21 | 77.8% |
| Other unapproved drugs | 3 | 11.1% |
| New drug applications (NDA) | 3 | 11.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 27 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Potassium chloride | 3 | 84 |
| Levetiracetam | 3 | 87 |
| Ephedrine sulfate | 3 | 26 |
| Fluorescein | 2 | 8 |
| Cyclophosphamide | 2 | 22 |
| Procainamide hydrochloride | 2 | 10 |
| Tirofiban hydrochloride | 2 | 2 |
| Isoproterenol hydrochloride | 2 | 13 |
| Phenobarbital sodium | 2 | 8 |
| Tranexamic acid | 1 | 39 |
| Methylene blue | 1 | 15 |
| Tacrolimus | 1 | 35 |
| Papaverine hydrochloride | 1 | 4 |
| Arsenic trioxide | 1 | 21 |
| Baclofen | 1 | 65 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 21 | 77.8% |
| Injection, solution | 6 | 22.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Cyclophosphamide | 14789-126 | Injection | Generic drugs (ANDA) | March 30, 2026 |
| Cyclophosphamide | 14789-125 | Injection | Generic drugs (ANDA) | March 30, 2026 |
| Tacrolimus | 14789-135 | Injection | Generic drugs (ANDA) | December 1, 2025 |
| Methylene Blue | 14789-119 | Injection, solution | Generic drugs (ANDA) | February 1, 2025 |
| Tranexamic Acid | 14789-115 | Injection, solution | Generic drugs (ANDA) | June 25, 2024 |
| Phenobarbital Sodium | 14789-128 | Injection, solution | Other unapproved drugs | December 6, 2023 |
| Phenobarbital Sodium | 14789-127 | Injection, solution | Other unapproved drugs | December 6, 2023 |
| Fluorescein | 14789-123 | Injection | Generic drugs (ANDA) | October 24, 2023 |
| Fluorescein | 14789-122 | Injection | Generic drugs (ANDA) | October 24, 2023 |
| Tirofiban Hydrochloride | 14789-102 | Injection | Generic drugs (ANDA) | September 25, 2023 |
| Tirofiban Hydrochloride | 14789-101 | Injection | Generic drugs (ANDA) | September 25, 2023 |
| Emerphed PFS | 14789-252 | Injection | New drug applications (NDA) | March 1, 2023 |
| Emerphed PFS | 14789-251 | Injection | New drug applications (NDA) | March 1, 2023 |
| Baclofen | 14789-161 | Injection | Generic drugs (ANDA) | February 22, 2023 |
| Papaverine Hydrochloride | 14789-121 | Injection | Other unapproved drugs | June 28, 2021 |
| Potassium Chloride | 14789-109 | Injection | Generic drugs (ANDA) | February 28, 2021 |
| Potassium Chloride | 14789-108 | Injection | Generic drugs (ANDA) | February 28, 2021 |
| Potassium Chloride | 14789-107 | Injection | Generic drugs (ANDA) | February 28, 2021 |
| Levetiracetam in Sodium Chloride | 14789-330 | Injection | Generic drugs (ANDA) | July 20, 2020 |
| Levetiracetam in Sodium Chloride | 14789-220 | Injection | Generic drugs (ANDA) | July 20, 2020 |
| Levetiracetam in Sodium Chloride | 14789-110 | Injection | Generic drugs (ANDA) | July 20, 2020 |
| Emerphed | 14789-250 | Injection | New drug applications (NDA) | May 15, 2020 |
| Arsenic Trioxide | 14789-600 | Injection | Generic drugs (ANDA) | November 19, 2018 |
| Isoproterenol Hydrochloride | 14789-015 | Injection, solution | Generic drugs (ANDA) | August 3, 2017 |
| Isoproterenol Hydrochloride | 14789-011 | Injection, solution | Generic drugs (ANDA) | August 3, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.